GGrantIndex
Sort

21,453 grants matching tuberculosis

HIV/TB in Uganda: Punctuated Antiretroviral Therapy

$1,290,372
Case Western Reserve University · R01 · FY2005 · AI

Development Of New Chemotherapeutics For Tuberculosis

$1,289,021
Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI

Development Of New Chemotherapeutics For Tuberculosis

$1,288,544
Clifton Barry · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

TUBERCULOSIS ELIMINATION AND LABORATORY PROGRAM

$1,288,057
Nancy Baruch · Maryland State Department Of Health · U52 · FY2011 · PS

Stellenbosch University Clinical Trials Unit (SUN-CTU)

$1,287,739
Mark Fredric Cotton · Stellenbosch University · UM1 · FY2017 · AI

Exploring the metabolism of non-replicating and drug-resistant TB

$1,286,564
Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Re-evaluating the Duration in Children of TB Treatment (REDUCE TB): A Phase 2 Duration Randomized Trial

$1,286,549
Anthony Joseph Garcia-Prats · University Of Wisconsin-Madison · U01 · FY2025 · AI

Pre-clinical Development of an Advanced Genexpert Test for Drug Resistant Mtb

$1,284,246
David Alland · Rbhs-New Jersey Medical School · R01 · FY2015 · AI

Chicago Clinical Trials Unit

$1,284,164
Babafemi O Taiwo · Northwestern University At Chicago · UM1 · FY2021 · AI

Vaccine and Treatment Evaluation Units

$1,282,926
Nadine Georges Rouphael · Emory University · UM1 · FY2025 · AI

TUBERCULOSIS ELIMINATION AND LABORATORY PROGRAM

$1,282,245
Nancy Baruch · Maryland State Department Of Health · U52 · FY2010 · PS

Natural History of HIV Infection in Injection Drug Users

$1,281,995
Johns Hopkins University · R37 · FY2003 · DA

JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT

$1,280,720
Johns Hopkins University · U01 · FY2002 · AI

Chemically Modified Peptide Nucleic Acids

$1,280,656
Daniel H Appella · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK

GENERAL CLINICAL RESEARCH CENTER

$1,280,194
Yeshiva University · M01 · FY2000 · RR

Integrated Care Clinics for IDUs in India: a cluster randomized trial

$1,279,936
Gregory M Lucas · Johns Hopkins University · R01 · FY2012 · DA

Johns Hopkins University Kampala-Nanning Clinical Trial Unit

$1,279,706
Mary Glenn Fowler · Johns Hopkins University · UM1 · FY2015 · AI

Genes/Pathways for Autophagy-dependent inhibition of Bacterial Infections

$1,278,288
Ramnik J Xavier · Washington University · U19 · FY2014 · AI

Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settings

$1,278,151
Adithya Cattamanchi · University Of California-Irvine · R01 · FY2024 · AI

Human MAIT celis in airway mucosal immune responses to intracellular infections

$1,277,830
David M. Lewinsohn · Oregon Health & Science University · U01 · FY2015 · AI

Human MAIT celis in airway mucosal immune responses to intracellular infections

$1,277,830
David M. Lewinsohn · Oregon Health & Science University · U01 · FY2014 · AI

Viable but Nonculturable Mtb

$1,277,246
Carl F Nathan · Weill Medical Coll Of Cornell Univ · U19 · FY2018 · AI

International Tuberculosis Clinical Research

$1,276,926
Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection

$1,276,503
Martin Alfons Gengenbacher · Hackensack University Medical Center · R01 · FY2023 · AI

Genes/Pathways for ATG Gene-dependent Inhibition of Viruses & Parasite Infection

$1,276,123
Herbert W Virgin · Washington University · U19 · FY2017 · AI